Company profile for Rallybio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. We are focused on rapidly advancing our pipeline of promising product candidates and on further expanding our portfolio to execute on our mission. The Company’s lead product candidate, RLYB211, is in development for the prevention of fetal and neon...
Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. We are focused on rapidly advancing our pipeline of promising product candidates and on further expanding our portfolio to execute on our mission. The Company’s lead product candidate, RLYB211, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
234 Church Street Suite 1020 New Haven, CT 06510
Telephone
Telephone
(203) 859-3820
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251105235045/en/Rallybio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates

BUSINESSWIRE
06 Nov 2025

https://www.businesswire.com/news/home/20250924016253/en/Rallybio-Completes-Dosing-of-First-Cohort-in-RLYB116-Phase-1-Confirmatory-PharmacokineticPharmacodynamic-Study

BUSINESSWIRE
25 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-03/rallybio-receives-125-million-equity-milestone-payment-from-recursion-for-advancement-of-rev102-pr

PHARMAWEB
03 Sep 2025

https://www.businesswire.com/news/home/20250805214081/en/Rallybio-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Updates

BUSINESSWIRE
07 Aug 2025

https://www.businesswire.com/news/home/20250707702845/en/Rallybio-Sells-Interest-in-REV102-Program-to-Recursion-Pharmaceuticals

BUSINESSWIRE
08 Jul 2025

https://www.fiercebiotech.com/biotech/rallybio-shifts-gears-cashing-out-recursion-pact-extend-runway

FIERCE BIOTECH
08 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty